A Phase Ib Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
A Phase Ib Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
Malignant Pleural Effusions (Mpe)
DRUG: JMKX000197|PROCEDURE: Tube thoracostomy drainage
AEs or SAEs, Up to approximately 36 days|Recommended Phase II dose (RP2D), Up to approximately 24 months
Puncture /drainage-Free Survival (PuFS), Up to approximately 24 months|Pleural effusion overall response (ORR), Up to approximately 24 months|Overall survival (OS), Up to approximately 24 months|Pharmacokinetics (Cmax), Up to approximately 7 days|Pharmacokinetics(Tmax), Up to approximately 7 days|Pharmacokinetics (t1/2), Up to approximately 7 days|Pharmacokinetics (AUC0-inf), Up to approximately 7 days|Pharmacokinetics (AUC0-t), Up to approximately 7 days|Amount of Drug Excreted Via Urine and Excrement, Up to approximately 48 hours
A Phase Ib Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion